Immunodominance and tumor escape

Seminars in Cancer Biology

Volumn 12, Issue 1, 2002, Pages 25-31

  Schreiber, H ^a   Wu, T H ^a   Nachman, J ^a   Kast, W M ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b LOYOLA UNIVERSITY HEALTH SYSTEM   (United States)

Author keywords

CD8+ T cells; Cross presentation; MHC Class I loss; Multiplicity; Tumor specific antigens; Variants

Indexed keywords

CD8 ANTIGEN; EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL; CANCER SURVIVAL; CONTROLLED STUDY; DENDRITIC CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; NONHUMAN; PHENOTYPE; TUMOR ESCAPE; TUMOR GROWTH;

EID: 0036150946     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1006/scbi.2001.0401     Document Type: Article

References (34)

1. Multiple tumour-specific antigens expressed on a single tumour cell
2. A unique tumor antigen produced by a single amino acid substitution
3. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma
4. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma
5. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes
6. A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma
7. Independent immunodominant and immunorecessive tumor-specific antigens on a malignant tumor: Antigenic dissection with cytolytic T cell clones
8. Malignant growth in the normal host after variant selection in vitro with cytolytic T-cell lines
9. Pecking order among tumor-specific antigens
10. Immunodominance deters the response to other tumor antigens thereby favoring escape: Prevention by vaccination with tumor variants selected with cloned cytolytic T cells in vitro
11. Ir-genes in H-2 regulate generation of anti-viral cytotoxic T cells. Mapping to K or D and dominance of unresponsiveness
12. Cytotoxic T-cell responses in mice infected with influenza and vaccinia viruses vary in magnitude with H-2 genotype
13. Immunodominance in the immune response to "multiple" histocompatibility antigens
14. Clonal restriction of the immune response to phosphorylcholine
15. Clonal nature of the immune response to phosphorylcholine. IV. Idiotypic uniformity of binding site-associated antigenic determinants among mouse antiphosphorylcholine antibodies
16. DNA sequence analysis of T-cell receptor genes reveals an oligoclonal T-cell response to a tumor with multiple target antigens
17. The immunodominant antigen of an ultraviolet-induced regressor tumor is generated by a somatic point mutation in the DEAD box helicase p68
18. Superdominance among immunodominant H-2Kb-restricted epitopes and reversal by dendritic cell-mediated antigen deliver
19. Stepwise immunologic selection of antigenic variants during tumor growth
20. Multiple cancers. Tumor burden permits the outgrowth of other cancers
21. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice
22. Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells
23. Antigenic cancer cells can grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy
24. The clonal evolution of tumor cell populations
25. Evolution of tumours and the impact of molecular oncology
26. A first or dominant immunization. I. Suppression of simultaneous cytolytic T cell responses to unrelated alloantigens
27. HLA and cancer: From research to clinical impact
28. Escape of human solid tumors from T-cell recognition: Molecular mechanisms and functional significance
29. A tumor escape variant that has lost one major histocompatibility complex class I restriction element induces specific CD8+ T cells to an antigen that no longer serves as a target
30. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines
31. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo
32. Dendritic cell/peptide cancer vaccines: Clinical responsiveness and epitope spreading
33. Prospects for T cell immunotherapy of tumours by vaccination with immunodominant and subdominant peptides
34. Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors